CD163 and myeloid sarcoma: In our recently published study [18], we demonstrated that sCD163 is a fair marker for MS disease, and so, the contribution of this study to MS diagnostics is not the individual biomarker levels as such, but rather the increased discriminatory powers in the combination of biomarkers.